SURVIVAL IN PATIENTS WITH HISTOLOGIC VARIANTS OF UROTHELIAL TYPE BLADDER CANCER
##plugins.themes.bootstrap3.article.main##
##plugins.themes.bootstrap3.article.sidebar##
Abstract
Objective: This study aims to determine the life expectancy of patients with histologic variants in urothelial type bladder cancer and the highest or lowest mortality rate in Hasan Sadikin Academic Medical Centre. Material & Methods: A cross-sectional study with total sampling. The samples in this study were patients with histologic variants of urothelial cell carcinoma bladder who received treatment at Hasan Sadikin Academic Medical Centre during the period of 2011 to 2022. Results: A total of 470 patients with a diagnosis of urothelial bladder cancer, 62 patients (13.19%) with histologic variants of urothelial bladder cancer treated with radical cystectomy or TURBT + intravesical chemotherapy at Hasan Sadikin Academic Medical Centre. The highest survival rate was in patients diagnosed with giant cell (66.7%) followed by small cell (50%) and glandular differentiation (40.0%). The 5-yearr survival rate of patients treated with radical cystectomy alone had a higher survival rate of 75.3% followed by radical cystectomy and adjuvant therapy, which was 75.2%. Conclusion: Histologic variants of bladder carcinoma that have the highest mortality rate are tropoblastic differentiation, nested type, micropappilary, and sarcomatoid with the lowest survival rate of 0%. Also, histologic variant of bladder carcinoma that has the lowest mortality rate is giant cell with a survival rate of 66.7%. Keywords: Bladder carcinoma, chemotherapy, trophoblastic differentiation.
##plugins.themes.bootstrap3.article.details##
Bladder carcinoma, Chemotherapy, Trophoblastic differentiation
Burger M, Catto JW, Dalbagni G, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013; 63: 234-41.
Bertz S, Hartmann A, Knüchel-Clarke R, et al. Specific types of bladder cancer. Pathologe. 2016; 37: 40-51.
Helpap B. Nonepithelial neoplasms of the urinary bladder. Virchows Arch. 2001; 439: 497-503.
Willis D, Kamat AM. Nonurothelial bladder cancer and rare variant histologies. Hematol Oncol Clin North Am. 2015; 29: 237-52.
Dahm P, Gschwend JE. Malignant non-urothelial neoplasms of the urinary bladder: a review. Eur Urol. 2003; 44: 672-81.
Grignon DJ, Ro JY, Ayala AG, et al. Primary adenocarcinoma of the urinary bladder. A clinicopathologic analysis of 72 cases. Cancer. 1991; 67: 2165-72.
Galsky MD, Iasonos A, Mironov S, et al. Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract. Urology. 2007; 69: 255-9.
Babjuk M, Burger M, Comperat EM et al: European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)d2019 update. Eur Urol. 2019; 76: 639.
Abdollah F, Gandaglia G, Thuret R et al: Incidence, survival and mortality rates of stagespecific bladder cancer in United States: a trend analysis. Cancer Epidemiol 2013; 37: 219.
Mickisch GH. Partial cystectomy for invasive bladder cancer. Eur Urol Suppl. 2005; 4(4): 67–71.
Klapheke A, Yap SA, Pan K, Cress RD. Sociodemographic disparities in chemotherapy treatment and impact on survival among patients with metastatic bladder cancer. Urol Oncol Semin Orig Investig. Elsevier. 2018; 36(6): 308.e19-308.e25.
Witjes JA, Compérat E, Cowan NC, De Santis M, Gakis G, Lebret T, et al. EAU guidelines on muscle-invasive and metastatic bladder cancer: Summary of the 2013 guidelines. Eur Urol. 2014; 65(4): 778–92.
Warrick JI. Clinical significance of histologic variants of bladder cancer. JNCCN J Natl Compr Cancer Netw. 2017; 15(10): 1268–74.
Gaertner RRW, Trpesk L, Johnson KC. A case–control study of occupational risk factors for bladder cancer in Canada. Cancer Causes Control. 2004; 15: 175–80.
Bilim V, Hoshi S. Prostatic urethra recurrence after transurethral resection of bladder tumor (TURBT) for non‐muscle‐invasive bladder cancer (NMIBC). Clin Case Reports. 2022; 10(1): 1–6.
Haga N, Tsubouchi K, Maruta H, Koguchi T, Hoshi S, Ogawa S, et al. Increase in circulating tumor cells in invasive bladder cancer after transurethral resection of bladder tumor. Anticancer Res. 2020; 40(8): 4299–307.